A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Myelofibrosis
Related studies linked through entity extraction aliases.
Study of Select Combinations in Adults With Myelofibrosis
- Status
- WITHDRAWN
- Phase
- PHASE1
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
- Status
- COMPLETED
- Phase
- N/A
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Actuate 1901: 9-ING-41 in Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study
- Status
- COMPLETED
- Phase
- N/A
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy
- Status
- UNKNOWN
- Phase
- N/A
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
- Status
- COMPLETED
- Phase
- NA
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Status
- TERMINATED
- Phase
- PHASE3
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
- Status
- COMPLETED
- Phase
- N/A
Individual Patient Compassionate Use of Fedratinib
- Status
- AVAILABLE
- Phase
- N/A